NCT00421226CompletedPhase 1
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Demonstrate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered as Intravenous Infusion and Subcutaneous Injection in Japanese Healthy Volunteers
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Novartis
- Enrollment
- 48
- Locations
- 1
- Primary Endpoint
- Safety and tolerability
Study Overview
Brief Summary
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ACZ885 administered via intravenous infusion and subcutaneous injection in healthy Japanese male volunteers.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 20 Years to 45 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Japanese healthy male subjects age 20 to 45 years of age, and in good health
- •At screening and baseline, the subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis.
- •Body mass index within the range of 18 to 28 kg/m2 and weigh 50 to 100 kg
Exclusion Criteria
- •Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Acetaminophen is acceptable. Treatment of any biologics within three months prior to dosing. Having live vaccinations within six months prior to dosing.
- •Participation in any clinical investigation within 4 months prior to dosing.
- •Donation or loss of 400 mL or more of blood within 3 months; donation or loss of 200 mL or more of blood within 1 month; or donation of component blood within 2 weeks prior to participation.
- •Significant illness (sinusitis, pneumonia, cystitis, sepsis, etc) within two weeks prior to dosing.
- •A past personal or close family medical history of cardiac disorders
- •History of:
- •fainting,
- •low blood pressure when standing,
- •abnormal heart rhythms
- •acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
- •Clinically significant drug allergy or history and complication of atopic allergy (asthma, urticaria, eczematous dermatitis)
- •Known hypersensitivity to the study drug or similar drugs
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or jeopardize participation in the study.
- •History of immunodeficiency diseases, including a positive HIV test result.
- •A positive Hepatitis B surface antigen (HBsAg), Hepatitis C or Syphilis test result.
- •Drug or alcohol abuse within the 12 months prior to dosing
- •Tuberculosis symptoms, complication of tuberculosis, contact with patients with suspected tuberculosis symptoms
- •Other protocol-defined inclusion/exclusion criteria may apply
Outcomes
Primary Outcomes
Safety and tolerability
Secondary Outcomes
- Pharmacokinetics and pharmacodynamics
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With MethotrexateRheumatoid ArthritisNCT00619905Novartis53
Active, not recruiting
Not Applicable
A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective - H2357Treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffectiveMedDRA version: 12.1Level: LLTClassification code 10018627Term: GoutEUCTR2009-017802-35-NLovartis Pharma Services AG220
Active, not recruiting
Not Applicable
A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffectiveEUCTR2009-015018-23-LTovartis Pharma Services AG220
Active, not recruiting
Not Applicable
A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffectiveTreatment and prevention of gout flares in patients with frequent flares and for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffectiveMedDRA version: 12.0Level: LLTClassification code 10018627Term: GoutEUCTR2009-015018-23-EEovartis Pharma Services AG220
Active, not recruiting
Not Applicable
A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective - H2356Treatment and prevention of gout flares in patients with frequent flares and for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffectiveMedDRA version: 12.0Level: LLTClassification code 10018627Term: GoutEUCTR2009-015018-23-DEovartis Pharma Services AG220